A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

Abstract

BackgroundAnlotinib may boost the efficacy of pancreatic cancer (PC) treatment if timely added to the GS regimen (Gemcitabine, Tegafur-gimeracil-oteracil potassium); however, no data has been published. This study evaluated the safety and efficacy of anlotinib in combination with the GS regimen(hereafter referred to as the A+GS regimen) in the first-line treatment of patients with unresectable or metastatic PC.MethodsPatients with unresectable or metastatic PC treated at Yueyang Central Hospital and Yueyang People’s Hospital between October 2018 and June 2022 were enrolled in this retrospective real-world investigation. Treatment efficacy was evaluated based on the overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and objective response rate (ORR), while the treatment safety was assessed by the frequency of major adverse events (AEs).ResultsSeventy-one patients were included in this study, 41 in the GS group and 30 in the A+GS group. The A+GS group had a longer mPFS than the GS group (12.0 months (95% CI, 6.0–18.0) and 6.0 months (95% CI, 3.0–8.1)), respectively (P = 0.005). mOS was longer in the GS+A group) when compared with the GS group (17.0 months (95%CI, 14.0–20.0) and 10.0 months (95% CI, 7.5–12.5)), respectively (P = 0.018). The GS+A group had higher ORR (50.0% vs 26.8%, P = 0.045) and DCR (83.3% vs 58.5%, P = 0.026). Furthermore, there were no grade 4-5 AEs and no treatment-related deaths, and no discernible increase in AEs in the GS+A group when compared with the GS group.ConclusionThe A+GS regimen therapy holds great promise in managing treatment-naive advanced PC, except that future prospective studies with larger sample sizes and multiple centers are required to determine its efficacy and safety.

Synergistic effect of additional anlotinib and immunotherapy as second‐line or later‐line treatment in pancreatic cancer: A retrospective cohort study

“…We also found that the addition of anlotinib to second‐line therapy was associated with longer OS compared with later‐line anlotinib ( p = 0.012). Our findings suggest that additional anlotinib may be a valid add‐on option recommended for PDAC patients, which shows similar results as reported by Zhan et al [ 25 ]. The advantage of anlotinib combination therapy may be due to the fact that PDAC has a special tumor microenvironment with dense interstitium, which is an important reason for the poor response of chemotherapy alone [ 26 ].…”

Single‐Cell Sequencing Reveals MYOF‐Enriched Monocyte/Macrophage Subcluster as a Favorable Prognostic Factor in Sepsis

“…[9] However, this binary M1/M2 classification is increasingly viewed as an oversimplification and is insufficient to capture the nuanced roles and heterogeneity of macrophages in sepsis. [10,11] Emerging evidence suggests that macrophages can polarize into a spectrum of functional states, influenced by their microenvironment. [12,13] This cellular heterogeneity may contribute to the complexity and variability in sepsis outcomes.…”